Yes, Zepbound is tirzepatide. Zepbound is simply the brand name that Eli Lilly uses to market tirzepatide for weight management. The active ingredient in every Zepbound pen is tirzepatide and nothing else. If you’ve seen both names floating around and wondered whether they’re different drugs, they’re not.
That said, there’s a reason for the confusion. Tirzepatide is also sold under a second brand name, Mounjaro, for a completely different purpose. And compounded versions of tirzepatide exist too, with important differences from the FDA-approved product. Here’s how it all fits together.
What Tirzepatide Actually Does
Tirzepatide is a dual-action medication. It activates two hormone receptors in your body: one for GIP and one for GLP-1. Both of these hormones are naturally released after you eat, and they play roles in blood sugar regulation, insulin release, and appetite signaling. Most older medications in this class only target one of those receptors. Tirzepatide targets both, which is a key reason it tends to produce more weight loss than single-receptor drugs.
The molecule is designed with an imbalance on purpose. It binds strongly to the GIP receptor (matching the strength of your body’s own GIP) but connects to the GLP-1 receptor with about five times weaker affinity than natural GLP-1. This matters because the GLP-1 pathway is largely responsible for nausea and vomiting, so dialing down its intensity while fully engaging the GIP pathway helps balance effectiveness with tolerability. The combined activation of both pathways in the brain produces a strong appetite-reducing effect, while actions on the pancreas enhance insulin secretion.
Two Brand Names, One Molecule
Eli Lilly deliberately created two separate brands for tirzepatide. Mounjaro was approved first, for treating type 2 diabetes in adults. Zepbound came later, approved specifically for chronic weight management. The molecule inside is identical.
The FDA approved Zepbound for adults with a BMI of 30 or higher, or a BMI of 27 or higher when at least one weight-related condition is present, such as high blood pressure, high cholesterol, type 2 diabetes, sleep apnea, or cardiovascular disease. Zepbound also carries a separate approval for moderate to severe obstructive sleep apnea in adults with obesity.
The two-brand strategy exists for practical reasons. It creates separate insurance coverage pathways (a weight management claim versus a diabetes claim), allows doctors to prescribe for the correct indication, and meets FDA labeling requirements. Your pharmacy may fill one or the other depending on what your prescriber writes and what your insurance covers, but the drug itself is the same.
Dosing and How It’s Taken
Zepbound is a once-weekly injection given under the skin in the stomach (at least two inches from the belly button), the thigh, or the upper arm. If you’re injecting in the upper arm, someone else needs to do it for you.
Everyone starts at 2.5 mg per week for the first four weeks. This initial dose is for your body to adjust, not a therapeutic dose. After four weeks, the dose increases to 5 mg. From there, your prescriber can bump it up in 2.5 mg steps, waiting at least four weeks between each increase, up to a maximum of 15 mg per week. The gradual escalation is designed to minimize side effects.
Pens should be stored in the refrigerator between 36°F and 46°F and kept in the original carton away from light. If needed, a single-dose pen can sit at room temperature (up to 86°F) for up to 21 days, and the KwikPen version for up to 30 days. Never freeze it, and if it does freeze, throw it away.
Common Side Effects
Gastrointestinal issues are the most frequent side effects, and they’re directly tied to the dose escalation period. In clinical trials, nausea affected 25% to 33% of people on Zepbound depending on the dose, compared to about 10% on placebo. Diarrhea occurred in 19% to 23% of participants, and vomiting in 8% to 12%. These rates were highest during the weeks when doses were being increased and declined over time as the body adjusted.
The FDA label also carries a boxed warning related to thyroid tumors. In animal studies, tirzepatide caused thyroid C-cell tumors. It’s unknown whether this risk applies to humans, but Zepbound is not prescribed for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2.
Compounded Tirzepatide Is Not the Same
If you’ve encountered cheaper tirzepatide from compounding pharmacies or online sellers, that is not equivalent to Zepbound. Compounded drugs are not reviewed by the FDA for safety, effectiveness, or quality before being sold. The FDA has received 545 adverse event reports associated with compounded tirzepatide as of July 2025.
The problems are wide-ranging. Some compounded tirzepatide products have arrived warm or without proper refrigeration, which can degrade the drug. The FDA has identified fraudulent products with fake pharmacy names on the label. Dosing errors have led to hospitalizations, often because patients were measuring incorrect amounts from multi-dose vials or because healthcare providers miscalculated doses. Some compounding pharmacies have also prescribed doses beyond what the FDA-approved label recommends, either higher single doses or faster escalation schedules.
The FDA has also warned companies selling unapproved tirzepatide labeled “for research purposes” or “not for human consumption” that was clearly being marketed to people for weight loss, complete with dosing instructions. If you’re considering a compounded version for cost reasons, the risks are meaningfully different from the brand-name product.